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Pharmacological mitigation of injuries caused by
high-dose ionizing radiation is an unsolved medical
problem. A specific nonlipid agonist of the type 2 G
protein coupled receptor for lysophosphatidic acid
(LPA2) 2-[4-(1,3-dioxo-1H,3H-benzoisoquinolin-2-yl)
butylsulfamoyl]benzoic acid (DBIBB) when adminis-
tered with a postirradiation delay of up to 72 hr
reduced mortality of C57BL/6 mice but not LPA2
knockout mice. DBIBB mitigated the gastrointestinal
radiation syndrome, increased intestinal crypt sur-
vival and enterocyte proliferation, and reduced
apoptosis. DBIBB enhancedDNA repair by augment-
ing the resolution of g-H2AX foci, increased clono-
genic survival of irradiated IEC-6 cells, attenuated
the radiation-induced death of human CD34+ he-
matopoietic progenitors and enhanced the survival
of the granulocyte/macrophage lineage. DBIBB
also increased the survival of mice suffering from
the hematopoietic acute radiation syndrome after
total-body irradiation. DBIBB represents a drug
candidate capable of mitigating acute radiation syn-
drome caused by high-dose g-radiation to the he-
matopoietic and gastrointestinal system.
INTRODUCTION
Humankind faces the challenge of mitigating injuries caused by
exposure to high levels of ionizing radiation, as happened during
the Tokai-mura, Fukushima, and Chernobyl nuclear plant disas-
ters, or explosion of a nuclear device (Dainiak et al., 2011;
DiCarlo et al., 2011; Igaki et al., 2008). In these types of disasters,
agents that can attenuate radiosensitive organ injury can only be
administered post hoc several hours, even days, after the time of206 Chemistry & Biology 22, 206–216, February 19, 2015 ª2015 Elseradiation exposure. Drugs that attenuate radiation injury under
such conditions are qualified as radiomitigators and will consti-
tute a class of medical countermeasures against radiation, an
as-yet nonexistent group of approved drugs. Lysophosphatidic
acid (LPA) is a growth factor-like lipid mediator that has been
shown to rescue cells from radiation-induced apoptosis and
cellular injury in vitro and in vivo (Deng et al., 2002). Stabilized
mimics of LPA have shown radiomitigative efficacy in animal
models of hematopoietic (HEM) and gastrointestinal (GI) acute
radiation syndrome (ARS) (Deng et al., 2007). In vitro receptor
add-back studies and experiments conducted with cells derived
from knockout (KO) mice for the Lpar2 gene indicate that this re-
ceptor subtype is necessary and sufficient to protect cells and
mice from radiation-induced cell death and injury to the gut
(Deng et al., 2007; Lin et al., 2007). Thus, improved nonlipid,
drug-like analogs specific to the LPA2 G protein coupled recep-
tor (GPCR) could provide drug candidates suitable for the treat-
ment of ARS. In silico drug discovery has identified 2-((3-(1,3-di-
oxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl)thio)-benzoic acid
(GRI-977143) nonlipid compound that activates LPA2 selectively
although not specifically (Kiss et al., 2012). GRI-977143, how-
ever, lacks the desired drug-like potency; it also has compro-
mised specificity because it is an antagonist of LPA3. We
undertook a medicinal chemistry approach guided by computa-
tional modeling using a pharmacophore developed from our ho-
mology model of the LPA2 ligand-binding pocket (Fujiwara et al.,
2005; Sardar et al., 2002). This approach has led to the identifi-
cation of LPA2-specific sulfamoyl benzoic acid (SBA) analogs
(Patil et al., 2014). Here we show that one of these LPA2-specific
analogs, DBIBB, is a highly effective mitigator of the ARS elicited
by exposure to high-dose (15.69 Gy) g-irradiation.RESULTS
Pharmacological Properties of DBIBB
We initiated studies with a pharmacophore using GRI-977143
docked into the LPA2 binding pocket as a template (Figure 1A)vier Ltd All rights reserved
Figure 1. Characterization of DBIBB as an LPA2 GPCR Agonist
(A) DBIBB docked into the LPA2 structure-based pharmacophore (Patil et al., 2014) incorporates three features: an anionic (head group, yellow), a hydrophobic
(linker), and a hydrophobic or aromatic (tail group, green). Three-dimensional spatial arrangements and the distances between the centroids are represented in
solid black lines. This model also shows the nearest vicinity of DBIBB docked into the ligand pocket with key interacting residues, shown as stick models. R3.28 is
a conserved residue in all EDG family LPA and S1P receptors that interact with the LPA phosphate. Lack of this interaction abolishes binding to either ligand.
Q3.29 determines the specificity for LPA versus S1P. TheW5.41, F6.44, andW6.48 residuesmakep-p interactions with the tail group important for activation and
potency.
(B) Designation of the key structural motifs in GRI-977143 that guided the design of DBIBB. The table shows the EC50/IC50, Emax/Imax values of GRI-977143,
DBIBB, and LPA 18:1 at LPA GPCR. *Vector controls were DKO MEF (LPA2), RH7777 (LPA1/3), CHO (LPA4), and B103 (LPA5) cells or engineered to express one
human LPA receptor ortholog (in parentheses). NE, no effect up to 10 mM of the ligand, the maximal concentration tested in the present experiments. Imax, %
inhibition of the Emax50 LPA 18:1 response for a given receptor subtype using 10 mM of the antagonist. #Represents EC50 values for LPA 18:1. EC50 and IC50
concentrations are given in mM for dose-response curves covering the 1 nM to 10 mM range. For determination of IC50 values, dose-response curves were
generated using an Emax50 concentration of LPA 18:1 for any given receptor subtype, and the ligand was co-applied in concentrations from 0.03 to 10 mM.
(C) DBIBB enhances the clonogenic survival of IEC-6 cells. IEC-6 cells were irradiated with increasing doses of g-irradiation from a 137Cs source at a dose rate of
4.4 Gy/min and plated. Cultures were treated30 min postirradiation with 10 mMDBIBB or vehicle and surviving colonies (± SD) were counted on postirradiation
day 8. (**p < 0.001 over control, n = 3)
(D) DBIBB and LPA inhibit radiation-induced caspase 3/7 activation in irradiated IEC-6 cells. IEC-6 cells were irradiated with 10 Gy at a dose rate of 4.4 Gy/min
from a 137Cs source. Test compounds were added to serum-free medium 1 hr after irradiation at the concentrations listed. Activity of caspases 3/7 (±SD) was
measured 24 hr after irradiation. (*p < 0.05, **p < 0.001 over irradiated vehicle control, n = 4).
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Figure 2. DBIBB Inhibits Radiation- and Genotoxic Stress-Induced Apoptosis In Vitro
(A) The effect of DBIBB on radiation-induced activation of initiator caspase 8. DBIBB and LPA inhibited apoptosis in LPA2 MEF but were inactive in vector MEF.
Increasing concentrations of the compounds or vehicle (3 mMBSA for LPA and 0.1% v/v DMSO for DBIBB) were added to the cells 1 hr after irradiation with 15 Gy
at 4.4 Gy/min from a 137Cs source. Caspase 8 activation was measured 4 hr postirradiation. Open bars indicate cells from vehicle-treated nonirradiated controls.
Bars and data points represent the mean ± SD of at least three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001 based on Student’s t test in this and
subsequent panels).
(B) Effects of DBIBB and LPA on radiation-induced activation of initiator caspase 9. Experimental conditions and statistical methods were the same as in (A).
(C) DBIBB dose dependently inhibits activation of executional caspases 3/7 in LPA2MEF. Cells were treated with indicated concentrations of the DBIBB 1 hr after
radiation exposure and caspase activity (mean ± SD, n = 3) was measured 4 hr later.
(legend continued on next page)
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to achieve LPA2 subtype agonist specificity by eliminating LPA3
antagonist activity and improving its potency. DBIBB had virtu-
ally identical overlay to GRI-977143, with the exception of the
linker region between the head and tail groups, where sulfur
was replaced by a sulfamoyl moiety (Figure 1B). The carboxy
group of the phenyl head group was predicted to interact with
R3.28, which has been experimentally proven to be a conserved
essential interaction in all EDG family LPA and S1P receptors
(Parrill et al., 2000;Wang et al., 2001) (Figure 1A). The Q.3.29 res-
idue that was previously shown to determine the specificity for
LPA versus S1P in the EDG GPCR family (Wang et al., 2001)
was predicted to interact with the hydroxyl moiety of the carboxy
group. When both of these residues were replaced with alanine,
the ligand binding and the activation of the EDG family receptors
were abolished (Wang et al., 2001). This suggests that the posi-
tion of the carboxy moiety on the phenyl head group might play
an important role in binding to LPA2.
The ligand properties of GRI-977143, DBIBB, and LPA 18:1
were characterized at LPA1, LPA3, LPA4, LPA5, and S1P1 recep-
tors (table insert in Figure 1B). Because GRI-977143 is both a se-
lective agonist of the LPA2 receptor and a weak antagonist of
LPA3 (Kiss et al., 2012), we also examined whether DBIBB had
antagonist or allosteric modulatory action on LPA1/3/4/5 GPCR.
The pharmacological characterization of DBIBB at LPA2 showed
nanomolar potency (EC50100 nM, a 33-fold increase over GRI-
977143); it was a specific agonist without activating or inhibiting
LPA1/3/4/5 receptors. Importantly, DBIBB lacked LPA3 antago-
nism. Altogether, these experiments indicated that DBIBB is a
specific agonist of the LPA2 receptor.
Radioprotective Efficacy of DBIBB In Vitro
Exposure to high levels of radiation can trigger apoptotic cell
death. We have shown earlier that LPA treatment within
1–2 hr after exposure of cultured cells to g-irradiation can
rescue apoptotically committed cells (Deng et al., 2007; Kiss
et al., 2012). The rat intestinal crypt epithelium-like cell line
IEC-6 is a nontransformed cell type with expression of LPA2,
which undergoes radiation- and genotoxic stress-induced
apoptosis that is attenuated by LPA (Deng et al., 2002, 2004,
2007). A clonogenic survival assay was performed to assess
whether DBIBB treatment increases IEC-6 cell survival when
administered 30 min after exposure to g-irradiation. DBIBB
applied postirradiation significantly (p < 0.01) increased the clo-
nogenic survival of IEC-6 cells in the 26 Gy dose range (Fig-
ure 1C). The increased clonogenicity of IEC-6 cells could be
due to the reduction of radiation-induced apoptosis and re-en-
try into the cell cycle. To test this hypothesis, we measured
activation of the main executioner caspases 3/7 in IEC-6 cells
exposed to g-irradiation. DBIBB dose dependently reduced(D) Inhibition of radiation-induced DNA fragmentation by LPA and DBIBB in DKO
inhibited DNA fragmentation in LPA2 MEF but showed no significant mitigative ac
irradiation, and DNA fragmentation (mean ± SD, n = 3) was measured 4 hr after
(E) LPA2 MEF or vector-transduced MEF cells were pretreated with LPA or DBIBB
activity (±SD, n = 3) was measured 5 hr after induction of apoptosis. **p < 0.01 a
(F) DBIBB and LPA reduce PARP-1 cleavage induced by g-irradiation. Subconflue
and were irradiated with 15 Gy. The cells were treated postirradiation with 10 mM
irradiation, the samples were collected and 30 mg of cell lysates was separated
DBIBB decreased the cleavage of PARP-1 in LPA2 MEF but failed to do so in ve
Chemistry & Biology 22, 206caspase 3/7 activation when applied 1 hr postirradiation to
IEC-6 cells (Figure 1D).
IEC-6 cells express multiple subtypes of LPA receptors (Deng
et al., 2007). To determine the role of the LPA2 receptor in the ra-
diomitigative actions of DBIBB, we used MEF from LPA13 LPA2
double KO (DKO) mice reconstituted with only the human LPA2
ortholog. We have previously shown that LPA can protect these
cells against radiation- or genotoxin-induced apoptosis (Deng
et al., 2007; E et al., 2009; Kiss et al., 2012, 2013). LPA2 MEF
and vector-transduced DKO MEF were exposed to 15 Gy of
g-irradiation at a dose rate of 4.4 Gy/min and treated with 1
and 3 mM of either LPA or DBIBB 1 hr after irradiation. Apoptosis
was monitored by measuring caspase 3/7, 8, and 9 activities or
DNA fragmentation. LPA and DBIBB reduced the activity of initi-
ator caspases 8, 9, and the executioner caspases 3/7 (Figures
2A–2C) in LPA2 MEF but had no significant attenuating effect in
vector control MEF. In LPA2 MEF but not in vector control
MEF, DBIBB dose dependently reduced DNA fragmentation
4 hr after irradiation (Figure 2D). LPA has been shown to rescue
apoptotically committed cells after adriamycin-induced DNA
damage (Lin et al., 2007). DBIBB also reduced caspase 3/7 ac-
tivity and DNA fragmentation in LPA2 MEF treated with adria-
mycin (Figure 2E; Figure S1).
Poly[ADP-ribose] synthase 1 (PARP-1) is an important enzyme
that regulates DNA repair, transcription, and cell survival (Ko and
Ren, 2012). ADP ribosylation enhances kinase activity of ATM
and DNA-dependent protein kinase, inhibits kinase activity of
ATR, and enables nuclear retention and transcriptional activity
of p53 and nuclear factor kB, in turn promoting DNA repair and
cell survival (Aguilar-Quesada et al., 2007; Kedar et al., 2008;
Ko and Ren, 2012). PARP-1 is inactivated by cleavage by cas-
pase 3 from a 116 kDa active form into an 89 kDa inactive
enzyme. Because LPA and DBIBB inhibited caspase 3 activity,
we measured PARP-1 cleavage 4 hr after irradiation in LPA2
MEF and vector MEF (Figure 2F). DBIBB and LPA inhibited
PARP-1 cleavage in LPA2 MEF but were ineffective in vector
MEF cells.
The DNA damage caused by ionizing radiation must be effec-
tively repaired to allow cell cycle progression and avoid onco-
genic or lethal mutations and aberrant chromosomes that could
lead to mitotic catastrophe (Kirsch et al., 2010). The phosphory-
lated histone 2AX on residue S139 (g-H2AX) is a marker of DNA
double-strand breaks, which is a marker to assess the effective-
ness of DNA repair by nonhomologous end joining (Lukas et al.,
2011). The effect of DBIBB on the resolution of g-H2AX-positive
cells was compared using flow cytometry (Figure 3A and 3B).
LPA2 and vector MEF were pretreated with 10 mM DBIBB for
15 min and g-H2AXhigh cells were measured using flow cytome-
try from 0.5 to 6 hr after 15 Gy irradiation. In LPA2 MEF, DBIBBMEF reconstituted with LPA2. DBIBB and LPA (symbols as in [A]) selectively
tion in vector MEF cells. The ligands or vehicle were added to the cells 1 hr after
irradiation.
, and apoptosis was induced using 1.7 mM adriamycin 1 hr later. Caspase 3/7
nd ***p < 0.001 using Student’s t test relative to vehicle.
nt LPA2MEF or vector MEF cells were serum-starved 1 hr before the irradiation
DBIBB, 3 mM LPA, or vehicle (3 mM BSA + 0.1% DMSO). Four hours after the
on a 10% SDS-PAGE and processed for Western blotting. Note that LPA and
ctor MEF (representative of three experiments).
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Figure 3. DBIBB Accelerates the Resolution
of gH2AXhigh Cells following Irradiation and
Activates the ERK1/2 Prosurvival Kinases
(A) Time course of gH2AXhigh resolution in LPA2
MEF and vector control MEF cells treated with
DBIBB or vehicle. Cells were pretreated for 15 min
with 10 mM DBIBB or vehicle (0.1% DMSO) and
irradiated with 15 Gy at 4.4 Gy/min. At the times
indicated, the cells were stained with anti-phos-
pho-H2AX eFluor660 and 104 events were re-
corded per sample using an LSR II flow cytometer.
In the 30 min panel, we indicate the position of the
gate (black line) used in subsequent panels to
identify gH2AXhigh cell subpopulations with the
highest intensity of gH2AX staining. Blue lines are
vehicle treated; red lines are DBIBB-treated sam-
ples. Note the separation of DBIBB-treated
gH2AXhigh cells from vehicle-treated cells and the
lack of separation between DBIBB- and vehicle-
treated vector control MEF (orange and green).
(B) Attenuation of g-H2AXhigh (mean ± SD, n = 3)
expression by DBIBB in LPA2 and vector-trans-
duced MEF using flow cytometry. This panel
shows the quantification of the experiment shown
in (A). Open bars represent vehicle-treated sam-
ples, filled bars represent DBIBB-treated samples.
Representative of three experiments. Note that
DBIBB accelerated the resolution of g-H2AX-ex-
pressing cells by significantly reducing gH2AXhigh
cells in LPA2 MEF (red) but not in vector MEF (blue)
at every time point tested. *p < 0.05 between
DBIBB-treated versus vehicle-treated LPA2 MEF;
#p < 0.05 between DBIBB-treated LPA2 versus
vector-transduced MEF.
(C) DBIBB and LPA activates ERK1/2 phosphory-
lation and concomitantly reduces g-H2AX levels
in LPA2 MEF but not in vector MEF cells. Cells
were irradiated and 4 hr later processed forWestern
blotting. Note the robust ERK1/2 phosphorylation
and the decreased g-H2AX levels in the LPA2 MEF
cells only (representative of three experiments).accelerated and significantly augmented the resolution of
g-H2AX foci as measured by g-H2AXhigh expression compared
with vehicle treatment. In contrast, in vector MEF, DBIBB failed
to elicit a significant decrease in g-H2AX. DBIBB accelerated
DNA repair by nonhomologous end joining indicated by the res-
olution g-H2AXhigh nuclei.
LPA-mediated activation of the extracellular response-regu-
lated kinases 1/2 (ERK1/2) is a key signaling step in DNA repair
as well as an important step in cell survival and proliferation.
DBIBB and LPA increased the phosphorylated active forms of
ERK1/2 and concomitantly reduced the level of g-H2AX in
LPA2 MEF. In contrast, both ligands were ineffective in vector
MEF cells (Figure 3C).
Efficacy of DBIBB Mitigating the Acute GI-ARS and
HEM-ARS
DBIBB was tested using a murine GI-ARS model of partial-
body irradiation (PBI) with shielding of the bone marrow con-
tained in the tibiae, fibulae, and paws, which effectively spares
5% of the bone marrow (Boggs, 1984; Booth et al., 2012;
PBI-BM5, Figure S2). A radiation dose of 15.69 Gy delivered at
1.47 Gy/min from a 137Cs in our facility led to lethal dose210 Chemistry & Biology 22, 206–216, February 19, 2015 ª2015 Else(LD)70/30 mortality in 10- to 12-week-old mice without supportive
care other than a gel food diet starting on postirradiation day 4.
Acute toxicology studies with daily administrations of up to
10 mg/kg of DBIBB for 10 days showed no visually observable
adverse effects and pathological findings at necropsy, indicating
the lack of toxicity in mice (data not shown). In this model, mice
developed GI-ARS, with peak mortality starting 8 days postirra-
diation and subsiding by postirradiation day 12. Crypt counts in
the small intestine culled on postirradiation days 1, 5, 10, and 20
from PBI-BM5 mice showed a precipitous decrease, reaching
nadir in the day 5 sample and gradually recovering to counts
near those seen in sham irradiated mice (Figure S3A). The num-
ber of apoptotic cell nuclei stained with the TUNEL reaction
showed an increase around the nadir of crypt counts and grad-
ually diminish as crypt numbers rebound (Figure S3B). These his-
topathological features are consistent with the manifestation of
GI-ARS. Thus, cohorts of C57BL/6 mice have been subjected
to this model with or without subcutaneous treatment with 1 or
10 mg/kg of DBIBB starting 26 ± 2 hr and repeated at 48 ± 2 hr
and 72 hr ± 2 hr postirradiation. The endpoint of the study was
mortality at postirradiation day 30, by which time the delayed
and life-threatening effects resulting from GI- and HEM-ARSvier Ltd All rights reserved
Figure 4. DBIBB Mitigates the GI-ARS
(A) Kaplan-Meier survival plots for groups of 15 C57BL/6 mice exposed to
15.69 Gy of 137Cs g-irradiation at a dose rate of1.5 Gy/min using a PBI-BM5
model. DBIBB dissolved in 1% ethanol/2% propanediol in PBS (vehicle) was
Chemistry & Biology 22, 206have manifested. In the vehicle-treated group, only one mouse
out of 14 per group survived to day 30, indicating that the
15.69 Gy dose resulted in 93% lethality (LD90/30, Figure 4A).
Although only twomice in the group treated with 1 mg/kg DBIBB
survived to day 30, the mean survival time in this dose group
increased significantly to 15 days from 8 days in the vehicle
group (p < 0.002, in Fisher’s exact test), effectively shifting
morbidity and mortality characteristics of the GI-ARS to the
typical period of the HEM-ARS. The group that received treat-
ments with 10 mg/kg DBIBB showed a significant increase in
survival, with 10 of 14 mice remaining alive on day 30 (p <
0.001). Subsequent to the peak of the GI-ARS mortality on post-
irradiation day 12, only 14% (2mice) of vehicle control mice were
alive, whereas survival in the 1 mg/kg and 10 mg/kg treatment
groups was 57% (8 of 14 mice) and 93% (13 of 14 mice), respec-
tively. These results collectively indicate that DBIBB administra-
tion starting at 26 ± 2 hr postirradiation at 10 mg/kg significantly
mitigated both 12-day and 30-day mortality.
DBIBBMitigatesRadiation-InducedApoptosis andCrypt
Loss and Augments Cell Proliferation
We repeated the PBI model by culling four mice on postirradi-
ation day 4.5 and determining the number of crypts, TUNEL,
and Ki67 proliferation marker-positive nuclei in sections of the
jejuna. In this experiment, C57BL/6 mice were again exposed
to our PBI-BM5 model and treated with 1, 3, or 10 mg/kg of
DBIBB or vehicle at 26 ± 2 hr, 48 ± 2 hr, and 72 ± 2 hr postir-
radiation. Surviving crypts were counted on H&E-stained sec-
tions taken at 3.5 and 7.5 cm distal to the pylorus. Jejuna
from mice treated with DBIBB showed a dose-dependent in-
crease in the number of surviving crypts compared with the
vehicle control (Figure 4B). Ki67-positive proliferating nuclei
also showed a dose-dependent increase that reached signifi-
cance compared with the vehicle group in the 10 mg/kg treat-
ment group (Figure 4C). TUNEL-positive apoptotic nuclei
counts showed a dose-dependent decrease in the treatment
groups (Figure 4C). These results indicate that the radiomitiga-
tive mechanism of action of DBIBB is mediated in part via
reduction of apoptosis and increased cell proliferation, leading
to increased crypt survival.administered starting at +26 ± 2 hr postirradiation for 3 days as a single daily
subcutaneous injection. DBIBB dose dependently increased survival during
the GI-ARS phase (days 8–12) and also the HEM-ARS phase (days 15–20),
particularly in the group treated with a 10 mg/kg daily dose.
(B) Mean crypt count per circumference in jejunum sections in groups (mean ±
SD, n = 4) of C57BL/6mice taken on postirradiation day 4.5. Crypt counts were
scored on H&E-stained paraffin-embedded sections by a board-certified
histopathologist blind to the treatments. Crypt counts showed a dose-
dependent increase that reached significance in the 3 and 10 mg/kg dose
groups (Student’s t test). The irradiation and treatment regimen was identical
to that in (A).
(C) The number of TUNEL-positive apoptotic and Ki67-positive proliferating
cells was counted using adjacent slides used for crypt counting in (B). The
count of TUNEL-positive nuclei (yellow bars, mean ± SD, n = 4) showed a
DBIBB dose-dependent decrease, which reached significance in the 10mg/kg
treatment group. Conversely, the number of Ki67 marker-positive nuclei (grey
bars, mean ± SD, n = 4) showed an increasing trend, which also reached
significance in the 10 mg/kg dose group. The immune-positive nuclei were
counted using the Nuclear Quantification algorithm (version 9) of the Aperio
Slide Digitizer instrument.
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Figure 5. DBIBBMitigates Radiation Injury to
the HEM System
(A) DBIBB applied decreases mortality in a TBI
model of HEM-ARS. WT C57BL/6 mice were
exposed to an LD70/30 dose of 8.5 Gy using 0.82 Gy/
min. The mice were treated with single daily sub-
cutaneous injections starting at +24 hr post-
irradiation and continuing for 3 more days (n = 15
mice/group). DBIBB caused a significant increase
in 30-day survival (p = 0.007 calculated using log-
rank test relative to vehicle). The low-dose 1 mg/kg
group showed a significant increase in mean sur-
vival time (p < 0.01) but not in 30-day survival over
the control group.
(B) Effect of delayed postirradiation administration
of DBIBB in the TBI model. Administration of
DBIBB was tested in a paradigm when the start of
treatment was delayed from +26 ± 2 hr to +72 ±
2 hr after irradiation. Mice in the 26-hr delayed
administration group received three additional
daily doses of 10 mg/kg at 26 ± 2 hr, 48 ± 2 hr,
72 ± 2 hr, and 96 ± 2 hr postirradiation, whereas
mice in the 72 hr delayed administration group
were injected at 72 ± 2 hr and 96 ± 2 hr post-
irradiation with DBIBB but received vehicle at
26 ± 2 hr and 48 ± 2 hr postirradiation. Survival in
the three groups is shown in the Kaplan-Meier
plots. Irradiation parameters were identical to
those in (A).
(C) The radiomitigative action of DBIBB requires
the LPA2 receptor. WT and LPA2 KO mice (n = 15,
age 16–18 weeks) on the C57BL/6 back-
ground were exposed to identical irradiation and
treatment conditions as shown in (A). Treatment
with DBIBB at 10 mg/kg failed to reduce 30-day
mortality significantly (p = 0.3, Fisher’s exact test)
and also failed to increase mean survival time in LPA2 KOmice, whereas the same treatment in WTmice significantly (p < 0.01) reduced mortality over the vehicle
control.
(D) Effect of DBIBB on the survival and HEM differentiation of irradiated human CD34+ progenitor cells. Purified CD34+ HEM progenitor cells in serum-free
Iscove’s MDM were irradiated with 4 Gy 137Cs g-irradiation at a dose rate of 0.85 Gy/min. After irradiation, cells were treated with a 1–10 mM concentration of
DBIBB for 4 hr. Cells were plated at 4,000 cells/plate in triplicate in MethoCult medium 4 hr after irradiation. Colonies of the different lineages were identified by
their characteristic morphology and counted on postirradiation day 14. Note that DBIBB increased the total colony number and colonies of the granulocyte/
macrophage lineage. Data are the mean ± SD of three independent experiments with cells from three different donors (*p > 0.05 and **p > 0.01 relative to vehicle).DBIBB Mitigates Mortality during the HEM-ARS Period
Mice treated with DBIBB after PBI exposure to 15.69 Gy showed
little mortality after day 15 during the manifestation of HEM-ARS.
This trend was most pronounced in the 10 mg/kg dose group.
We hypothesized that this lack of mortality during the HEM-ARS
period could be due not only to recovery of the HEM system
from the shielded bone marrow but also to protective and regen-
erativeeffectsofDBIBBonhematopoiesis.To test thishypothesis,
we exposedC57BL/6mice to 8.5Gy total-body irradiation (TBI) at
0.82Gy/min (LD60/30).Micewere injected subcutaneouslywith 1
or 10 mg/kg DBIBB starting at 26 ± 2 hr and repeated at 48 ± 2 hr
and 72 hr ± 2 hr postirradiation (Figure 5A). Thirty-day survival in
the 1 mg/kg treatment group, although 20% higher than in the
vehicle control group, did not reach significance using Fisher’s
exact test. In contrast, the10mg/kgcohort showeda50%survival
benefit over the control (p=0.007). In this treatment group,mortal-
ity began on day 16 and no animal was lost after day 18, which is
consistent with the typical manifestation of the HEM-ARS.
We also tested whether DBIBB could mitigate mortality when
the start of treatment was delayed from +26 ± 2 hr to +72 ± 2 hr212 Chemistry & Biology 22, 206–216, February 19, 2015 ª2015 Elseafter irradiation. Mice in the 26 hr delayed administration group
received three additional daily doses of 10 mg/kg DBIBB at
26 ± 2 hr, 48 ± 2 hr, 72 ± 2 hr, and 96 ± 2 hr postirradiation,
whereas mice in the 72 hr delayed administration group were in-
jected once more at 96 ± 2 hr postirradiation with DBIBB but
received vehicle at 26 ± 2 hr and 48 ± 2 hr postirradiation, keep-
ing the number of handlings and injections identical in all groups.
On day 30, only 3 out of 15 vehicle control mice were alive (Fig-
ure 5B). In the group of mice treated with DBIBB starting with
a +24 hr postirradiation delay, 13 of 15 survived (87%), whereas
in the +72 hr delayed administration group, 14 of 15 mice (93%)
remained alive on day 30. No deaths occurred in either treatment
group prior to day 12 or after day 20. In the vehicle group, mice
began dying on day 8 and continued to die until postirradiation
day 25. These results suggest that DBIBB shows efficacy in
mitigating HEM-ARS even if treatment is delayed by 72 ± 2 hr af-
ter TBI.
We next examined whether DBIBB can rescue LPA2 KO
mice from HEM-ARS. Wild-type (WT) or LPA2 KO mice were
exposed to 8.5 Gy TBI and treated with three daily subcutaneousvier Ltd All rights reserved
10 mg/kg doses of DBIBB or vehicle starting at +26 ± 2 hr post-
irradiation. Treatment of LPA2 KO mice with DBIBB caused no
significant mitigation of mortality (p = 0.3, Figure 5C), whereas
the same treatment caused a significant reduction in mortality
in WT mice (p < 0.007). We evaluated whether DBIBB treatment
increases the abundance of cKit-Lin-Sca-1 positive HEM pro-
genitors in the shielded bone marrow from the tibia isolated on
postirradiation day 4 from mice exposed to the PBI-BM model.
These experiments showed an increase in the number of Kit-
Lin-Sca-1 positive cells in the tibial bone marrow of DBIBB-
treated mice, but even although the experiments were repeated
three times, the increase did not reach significance due to the
low number of these cells (n = 6 mice per group; Figure S4).
To extend the radioprotective effect of DBIBB on hematopoi-
esis between species, we tested human HEM progenitor cells,
which predominantly express LPA2 among multiple LPA recep-
tor subtypes (Figure S5). Purified CD34+ progenitor cells derived
from human cord blood were irradiated with 4 Gy prior to 2 hr
treatment with increasing concentration of DBIBB or vehicle.
After this treatment, the cells were transferred to MethoCult me-
dium for the determination of survival and clonogenic capacity
(Figure 5D). DBIBB significantly increased the total number of
colonies and specifically enhanced the survival of the granulo-
cyte/macrophage lineages. This in vitro result corroborates our
findings concerning the radiomitigation in DBIBB-treated TBI
mice and extends it to HEM progenitors of the human species.
DISCUSSION
Earlier studies have shown that the pan-LPA receptor agonist
octadecenyl thiophosphate decreased the loss of intestinal
stem cells and promoted crypt survival in WT but not in LPA2
KO mice (Deng et al., 2007). The weak LPA2-selective agonist
GRI-977143 decreased mortality in an HEM-ARS model when
administered at 24 hr postirradiation. LPA2 receptors are widely
expressed and are detectable in intestinal (Munoz et al., 2012),
HEM (Evseenko et al., 2013; Ortlepp et al., 2013), and embryonic
stem cells (Costa et al., 2013) which play an important role in
postirradiation tissue regeneration. Starting with a pharmaco-
phore based on GRI-977143, we developed DBIBB, which is a
specific agonist of the LPA2 receptor subtype without detectable
modulatory effects of the other LPA GPCR and the S1P1 recep-
tor. DBIBB was characterized using multiple in vitro and in vivo
assays to evaluate its effects on cell and organ injury caused
by g-radiation and adriamycin. DBIBB exerted dose-dependent
inhibition of caspases 3, 7, 8, and 9, reduces DNA fragmentation,
enhanced DNA repair via LPA2, and increased clonogenic
survival of IEC-6 cells. These results establish that specific acti-
vation of LPA2 alone is sufficient to protect cells from radiation-
and chemical genotoxin-induced cell death.
Preserving the genetic integrity of the DNA after ionizing radi-
ation exposure is a pivotal step that can decide whether the cell
will be able to clear the checkpoints in cell cycle progression and
prevent mitotic catastrophe due to chromosomal aberrations. A
radiationmitigator ideally should augment the repair of radiation-
induced DNA damage. Thus, the present findings showing that
the resolution of the phosphorylated form of the histone H2AX
was accelerated in LPA2 MEF but not in vector MEF after expo-
sure to DBIBB are of importance. Kirsch et al. (2010) proposedChemistry & Biology 22, 206that due to incomplete DNA repair, some intestinal epithelial cells
may undergo aberrant mitosis and die by mitotic catastrophe
and not by apoptotic death. These authors showed that p53
and its downstream target the cyclin-dependent kinase inhibitor
p21 can attenuate this type of cell loss, which manifests within
the first 4 hr after radiation injury. LPA2 has been shown to acti-
vate p53 (Jiang et al., 2011; Kortlever et al., 2008; Lee et al.,
2013) and p21 (Kanehira et al., 2012; Wu et al., 2011). Thus,
DBIBB via LPA2might activate p53 and downstream p21 to exert
its radiomitigating effect. However, in our studies, DBIBB was
administered >24 hr postirradiation. To what extent the late
phase of radiation-induced cell loss leading to GI-ARS involves
mitotic catastrophe-mediated versus apoptotic cell death will
have to be addressed in future studies. Kirsch et al. (2010)
showed that inhibition of the intrinsic apoptotic pathway by
knocking out Bak-1 and Bax in HEM and endothelial cells pre-
vented the manifestation of the HEM-ARS-related in mice. Our
results demonstrating that DBIBB inhibited the activation of the
intrinsic apoptotic pathway are consistent with such a mecha-
nism and might provide an explanation for the increased survival
of mice in the HEM-ARS model. Whether DBIBB-mediated
attenuation of the intrinsic apoptosis pathway or mitotic catas-
trophe play a role in the postirradiation survival of radiation-resis-
tant Bmi1 and/or radiation-sensitive Lgr5 marker-positive intes-
tinal stem cells will have to be examined in future experiments.
The application of LPA2 MEF together with vector-transduced
DKO MEF control cells in every step of the in vitro characteriza-
tion of DBIBB provided important genetic evidence that the radi-
ation mitigating actions of this compound are mediated by the
LPA2 receptor. DBIBB protected rat intestinal crypt-derived
IEC-6 cell line and human CD34+ HEM progenitor cells that
endogenously expresses LPA2 among other LPA receptor sub-
types, establishing its cross-species efficacy as a radiomitigator.
Our efforts to demonstrate that DBIBB enhances the population
of Lim-cKit-Sca-1 positive HEM progenitor cells in the shielded
bone marrow on postirradiation day 4 showed an increment,
but further extensive experiments will be necessary to charac-
terize the effects of this compound on hematopoiesis, which
are beyond the scope of the present study. DBIBB in murine
ARS models showed a significant radiomitigative effect on the
GI system, indicated by decreased apoptosis, increased crypt
survival, increased cell proliferation, and regeneration. These ef-
fects on the GI tract combined with the increased recovery of the
HEM system, whichmight also indirectly regulate GI recovery via
soluble factors, could provide an explanation for the increased
survival of mice following exposure to high doses of g-radiation.
DBIBB was effective in mitigating HEM-ARS in the TBI model
when administration began up to 72 hr postirradiation. There
are few reports in the literature on radioprotective and radiomiti-
gative compounds (Anzai et al., 2013; Basile et al., 2012; Berbee
et al., 2011; Burdelya et al., 2008; Gaberman et al., 2013;
Gao et al., 2012; Geiger et al., 2012; Haydont et al., 2007; Kim
et al., 2013; Saha et al., 2011; Sridharan et al., 2013; Wang
et al., 2013); however, most of these interventions lose efficacy
when administered 24 hr post injury or they are efficacious
only in treating single-organ injury. The effective protection we
detected with delayed administration of DBIBB indicates that
the initial tissue damage sustained during the first 72 postirradi-
ation hours can be effectively treated. The signal transduction–216, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 213
mechanisms responsible for this delayed-onset radiomitigative
effect linked to selective activation of LPA2 in radiosensitive
stem/progenitor cells in the tissues remain unclear but are likely
to involve multiple downstream secondary targets (E et al., 2009;
Lin et al., 2007, 2010).
The results of our study collectively support the potential me-
dicinal utility of specific LPA2 receptor agonists in mitigating GI
and HEM injury elicited by high doses of ionizing radiation. The
delayed efficacy of DBIBB at 72 hr after radiation injury lends
previously unavailable experimental evidence in support of the
concept of radiation mitigation and underlines the feasibility
treatment protocols beginning days after exposure. The present
results provide evidence that a single pharmacological agent
might be capable of attenuating both HEM and GI injury caused
by high doses of ionizing radiation.
SIGNIFICANCE
Medical treatment of complex injuries caused by high-dose
ionizing radiation is an unsolvedmedical problem. Radiation
mitigators (a new class of radiation countermeasures effec-
tive when administered several hours, even days, after radi-
ation exposure) are needed. Activation of the LPA2 GPCR for
the growth factor-like lipid mediator LPA was shown to
attenuate cell injury caused by ionizing radiation; however,
no LPA2-specific agonist has been identified before. We
identified 2-[4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)
butylsulfamoyl] benzoic acid (DBIBB) as an LPA2-specific
agonist. Using MEF from LPA1/2 DKO mice reconstituted
with only the LPA2 GPCR, DBIBB was found to rescue these
cells from radiation- or genotoxin-induced death and
enhanced DNA repair by reducing g-H2AX. In WT mice, but
not in LPA2 KO mice, DBIBB reduced mortality caused by
total-body g-irradiation and was effective even when treat-
ment started +72 hr post exposure. In a PBI model with
shielding of 5% of the bone marrow, DBIBB dose depen-
dently decreased mortality, increased the number of surviv-
ing intestinal crypts, and reduced the number of apoptotic
nuclei. DBIBB also reduced radiation-induced death of hu-
man CD34+ HEMprogenitor cells. DBIBB represents the first
radiomitigator small molecule drug candidate capable of
reducing mortality caused by the HEM and GI ARSs.
EXPERIMENTAL PROCEDURES
Induction of Apoptosis
In all experiments, apoptosis was induced either by direct g-irradiation or
by the radiomimetic chemotherapeutic adriamycin. In radiation-induced
apoptosis experiments using caspase activation or DNA fragmentation assays
as endpoints, MEF cells were plated the day before the irradiation in 48-well
plates at a density of 2 3 104 cells/well. One hour before irradiation, the full-
growth medium was changed to serum-free medium, and the cell cultures
were exposed to a dose of 15 Gy 137Cs g-irradiation (4.4 Gy/min). One hour
postirradiation, MEF cells were treated either with vehicle (BSA or DMSO),
LPA (1–3 mM), DBIBB (1, 3 or 10 mM). Caspase activation and DNA fragmenta-
tion were measured 4 hr after the irradiation. For the adriamycin-induced
(1.7 mM) apoptosis experiments, MEF cells were plated in 48-well plates (2 3
104 cells/well) and cultured overnight in complete growth medium. The next
morning, the growthmedium was replaced by serum-starved medium supple-
mented with 0.1% (w/v) BSA. Cells were pretreated for 1 hr with LPA (1–3 mM),
DBIBB (1, 3 or 10 mM), or vehicle (BSA for LPA or 0.1%DMSO for DBIBB). Cas-214 Chemistry & Biology 22, 206–216, February 19, 2015 ª2015 Elsepase activation and/or DNA fragmentationweremeasured to assess apoptosis
5 hr after adriamycin exposure. In the irradiation-induced apoptosis experi-
ments of IEC-6 cells, the cellswere plated in 48-well plates in completemedium
(3.53 104 cells/well). On the next day, the completemediumwas replacedwith
serum-starvation medium for 18–24 hr before the irradiation. To induce
apoptosis, IEC-6 cells were exposed to 10 or 15 Gy g-irradiation as noted for
a given experiment at a rate of 4.4 Gy/min. One hour after irradiation, the
medium was replaced with a fresh serum-starvation medium and IEC-6 cells
were treated either with vehicle (BSA or 0.1 DMSO), LPA (1–3 mM), or DBIBB
(1, 3, 10, and 30 mM). Six hours after irradiation, the medium was changed
and the cells were treated with fresh compounds at the concentrations
mentioned above. Caspase activation was measured 24 hr after irradiation.
In a separate plate, sister cultures were plated for nonirradiated vehicle treat-
ment (BSA or DMSO) at the same density as used for irradiation.
Caspase Activation Assay
To measure caspase activation, the cells were lysed in 50 ml of Caspase-Glow
reagent. Caspase-Glo 3/7, Caspase-Glo 8, and Caspase-Glo 9 were pur-
chased from Promega and used as described previously (Kiss et al., 2013).
The caspase activity was calculated as the mean ± SD for triplicate wells for
every experimental group.
DNA Fragmentation ELISA
DNA fragmentationwasquantifiedbyusing theCell DeathDetectionELISAPLUS
kit (Roche Diagnostics) and normalized to protein concentration. Protein con-
centration was measured using the BCA Protein Assay Kit (Thermo Fisher Sci-
entific). DNA fragmentation was determined and expressed as absorbance at
405 nm/min/mg protein as described previously (Kiss et al., 2013).
Quantification of g-H2AXhigh Levels
LPA2 DKO MEF and vector DKO MEF cells were plated in at 1.5 3 10
5 cells/
well density in 1.5 ml DMEM supplemented with 2 mM l-glutamine and 10%
FBS. Next day, the cells were serum starved for 2.5 hr, pretreated for 15 min
with either 10 mM DBIBB, 10 mM LPA, or vehicle (0.1% DMSO), and irradiated
with 15 Gy at 4.4 Gy/min. After irradiation, the mediumwas replaced with fresh
serum-free medium containing either vehicle or DBIBB. At times indicated
(15 min to 6 hr), the cells were trypsinized, centrifuged, and stained with
anti-phospho-H2AX (S139) eFluor660 (Ebioscience) using the Foxp3/Tran-
scription Factor Staining Buffer Set (Biolegend) following the manufacturer’s
protocol. Ten thousand events per sample weremeasured with flow cytometry
using an LSR II instrument (Becton Dickinson) and analyzedwith the FACSDiva
software (Becton Dickinson). Gating was set in all samples to reveal an inten-
sively stained gH2AXhigh population of cells that allowed the time course of res-
olution to be followed, i.e. the progression of ds-DNA repair.
ForWestern blotting, cell lysates were harvested 4 hr after irradiation in RIPA
buffer (PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS). Protein con-
centrations were determined using the Pierce BCA method (Thermo Scienti-
fic). For detection of phosphorylated phosphorylated ERK1/2 (Cell Signaling),
20 mg of protein samples was separated on a 12% SDS-PAGE gel and trans-
ferred onto a nitrocellulose membrane. For detection of phosphorylated H2AX
(Cell Signaling) and b-actin (Sigma Aldrich), 15 mg of protein samples was
separated on 16% SDS-PAGE gels. Membrane was blocked with 5% milk in
Tris-buffered saline, 0.05% Tween-20 (TBST) for 1.5 hr followed by overnight
incubation with primary antibodies at 4C in 5% BSA TSBT. Membrane was
washed with TBST and incubated with secondary antibodies for 1 hr, and
finally washed in TBST. For monitoring, PARP-1 cleavage MEF cells were
plated the day before the experiment. Next day the cells were serum starved
1 hr before the irradiation and irradiated with 15 Gy at 4.3 G/min. The cells
were treated 10 min after the irradiation with 10 mM DBIBB or 3 mM LPA, or
vehicle (3 mMBSA + 0.1%DMSO). Four hours after the irradiation, the samples
were collected for protein extraction and 30 mg of the cell lysates was run on a
10% SDS-PAGE. The rabbit anti-PARP-1 antibody was from Cell Signaling
and used at 1:1000 dilution. Pierce SuperSignal West Pico ECL kit (Thermo
Scientific) was used to visualize the membrane.
Mouse PBI and TBI Irradiation Models
Experimental procedures were reviewed and approved by the Institutional An-
imal Care and Use Committee of the University of Tennessee Health Sciencevier Ltd All rights reserved
Center. Eight- to 10-week-old C57BL/6 female mice (Jackson Laboratories) or
LPA2 KO mice on the C57BL/6 background (kind gift of Dr Jerold Chun,
Scripps Institute) bred in our colony, were acclimated for at least 1 week in
the vivarium. All irradiations were performed using a 137Cs g source (J.L. Shep-
herd, Mark I, Model 25). Mice were housed in Allentown Biocontainment cages
in the Regional Biocontainment Laboratory of the University of Tennessee
Health Science Center Memphis. The mice received no supportive care but
were provided with gel food packs (Diet Gel 76A, Clear H2O, g-irradiation ster-
ilized) on postirradiation day 4 andwere fed sterilized chow (Harlan Teklad LM-
485 mouse/rat diet, g-irradiation sterilized) throughout the study, ad libitum
with autoclaved tap water. Animals were group housed with a maximum of 4
animals per cage using autoclaved bedding, enrichment blocks, and nestlets.
Radiation field mapping and calibration by ion chamber dosimetry was done
by the manufacturer at installation. Referencing dosimetry was conducted in
May, 2012, indicating an average dose rate of 1.47 Gy/min. In addition, routine
validation and quality control measurements of exposure rates and exposure
rate mapping in the chamber at positions of interest was conducted by a Certi-
fied Health Physicist using a calibrated RadCal 0.6 cm3 therapy grade ion
chamber/electrometer system. High-dose thermoluminescent dosimeters
were used in most irradiations to validate the actual dose delivered to the
mice (MD Anderson Cancer Center Radiation Dosimetry Services). The
isodose field was validated using Gafchromic (radiochromic) film for high-
dose dosimetry (10–50 Gy; Ashland).
The PBI model with bone marrow sparring that we used is similar to that
used by Booth and colleagues of the MCART Consortium (Booth et al.,
2012). In our PBI model, mice were anesthetized with ketamine (87 mg/kg)
and xylazine (13 mg/kg, intraperitoneally) and placed in a plexiglass restrainer
such that the legs below the knee were shielded. The shielding protected
tibiae, fibulae, and the paws from radiation that contained 5% of the bone
marrow (Boggs, 1984). The effectiveness of shielding was verified in randomly
selectedmice by histological examination (see Figure S2). Mice placed into the
isodose field of the irradiator were irradiated in groups of eight.
During the model development phase, mice were exposed to radiation
doses from 6 to 18 Gy and a dose-response curve was generated using
logit-probit analysis for day-10 and day-30 mortality. In this model, 15.69 Gy
delivered at a dose rate of 1.47 Gy/min yielded an empiricalLD85/10 mortality
with some seasonal variation, with the peak occurring between postirradiation
days 8 and 10. Histological examination of the intestinal radiation damage
confirmed the development of the GI-ARS in all animals.
The TBI model we used was similar to that described by Plett et al. (2012) in
the MCART Consortium of the National Institute of Allergy and Infectious Dis-
eases. In our TBI model, the 8–10-week-old C57BL/6 or LPA2 KO mice (15–16
animals/group) were exposed to 8.5 Gy of g-irradiation from the 137Cs g source
at a dose rate of 0.82 Gy/min in a rotating chamber. This radiation dose,
which yielded an LD60/30 mortality with mean survival time of 22 ± 2.6 day
(SD), was selected based on a partial dose-response curve that spanned the
dose range between 8 and 10 Gy in 0.5 Gy increments. The mice were housed
and maintained under identical conditions as described above for the PBI
model without supportive care. Twenty-six ± two hours after the irradiation,
the animals were treated with either vehicle or DBIBB via subcutaneous injec-
tion. Animal survival was recorded twice daily up to 30 days, which was the
endpoint of these experiments. Statistical testing of the survival data was
done by Fisher’s exact test.
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